Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Clinical efficacy of melittin in the treatment of cats infected with the feline immunodeficiency virus.

Hartmann AD, Wilhelm N, Erfle V, Hartmann K.

Tierarztl Prax Ausg K Kleintiere Heimtiere. 2016 Dec 5;44(6):417-423. Epub 2016 Nov 3. English, German.

PMID:
27808347
2.

Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes.

Becker PD, Nörder M, Weissmann S, Ljapoci R, Erfle V, Drexler I, Guzmán CA.

Vaccines (Basel). 2014 Jul 22;2(3):581-600. doi: 10.3390/vaccines2030581.

3.

Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic.

Dembek CJ, Kutscher S, Allgayer S, Russo C, Bauer T, Hoffmann D, Goebel FD, Bogner JR, Erfle V, Protzer U, Cosma A.

J Clin Virol. 2012 Oct;55(2):114-20. doi: 10.1016/j.jcv.2012.06.017. Epub 2012 Jul 13.

PMID:
22795599
4.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W, Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Buttò S, Fanales-Belasio E, Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H.

J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005. Epub 2011 Sep 22.

PMID:
21963950
5.

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.

Nörder M, Becker PD, Drexler I, Link C, Erfle V, Guzmán CA.

PLoS One. 2010 Jun 30;5(6):e11400. doi: 10.1371/journal.pone.0011400.

6.

Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection.

Dembek CJ, Kutscher S, Heltai S, Allgayer S, Biswas P, Ghezzi S, Vicenzi E, Hoffmann D, Reitmeir P, Tambussi G, Bogner JR, Lusso P, Stellbrink HJ, Santagostino E, Vollbrecht T, Goebel FD, Protzer U, Draenert R, Tinelli M, Poli G, Erfle V, Malnati M, Cosma A.

AIDS Res Ther. 2010 Jul 2;7:20. doi: 10.1186/1742-6405-7-20.

7.

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, Goebel FD, Erfle V, Cosma A.

Gene Ther. 2010 Nov;17(11):1372-83. doi: 10.1038/gt.2010.90. Epub 2010 Jun 10.

PMID:
20535218
8.

Elevated Epstein-Barr virus loads and lower antibody titers in competitive athletes.

Hoffmann D, Wolfarth B, Hörterer HG, Halle M, Reichhuber C, Nadas K, Tora C, Erfle V, Protzer U, Schätzl HM.

J Med Virol. 2010 Mar;82(3):446-51. doi: 10.1002/jmv.21704.

PMID:
20087932
9.

The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.

Di Lullo G, Soprana E, Panigada M, Palini A, Agresti A, Comunian C, Milani A, Capua I, Erfle V, Siccardi AG.

J Virol Methods. 2010 Feb;163(2):195-204. doi: 10.1016/j.jviromet.2009.09.016. Epub 2009 Sep 22.

PMID:
19778556
10.

Unsung hero Robert C. Gallo.

Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.

Science. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. No abstract available.

PMID:
19131607
11.

Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.

Di Lullo G, Soprana E, Panigada M, Palini A, Erfle V, Staib C, Sutter G, Siccardi AG.

J Virol Methods. 2009 Mar;156(1-2):37-43. doi: 10.1016/j.jviromet.2008.10.026. Epub 2008 Dec 10.

PMID:
19038289
12.

The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S, Tambussi G, Bogner JR, Stellbrink HJ, Goebel FD, Lusso P, Tinelli M, Poli G, Erfle V, Pohla H, Malnati M, Cosma A.

AIDS Res Ther. 2008 Oct 6;5:22. doi: 10.1186/1742-6405-5-22.

13.

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

Schulze K, Staib C, Schätzl HM, Ebensen T, Erfle V, Guzman CA.

Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.

PMID:
18805454
14.

Therapeutic vaccination reduces HIV sequence variability.

Hoffmann D, Seebach J, Cosma A, Goebel FD, Strimmer K, Schätzl HM, Erfle V.

FASEB J. 2008 Feb;22(2):437-44. Epub 2007 Oct 10.

PMID:
17932027
15.

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.

Bråve A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, Boberg A, Engström G, Reiland S, Cosma A, Drexler I, Hinkula J, Wahren B, Erfle V.

Infect Agent Cancer. 2007 Jul 10;2:14.

16.

Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, Erfle V.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):782-93.

PMID:
17604541
17.

Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.

El-Gogo S, Staib C, Meyr M, Erfle V, Sutter G, Adler H.

Vaccine. 2007 May 16;25(20):3934-45. Epub 2007 Mar 6.

PMID:
17433507
18.

Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.

Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V.

J Med Primatol. 2007 Feb;36(1):2-9.

PMID:
17359459
19.

The anticancer drug imatinib induces cellular autophagy.

Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, Schätzl HM.

Leukemia. 2007 May;21(5):936-42. Epub 2007 Mar 1.

PMID:
17330103
20.

HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner.

Lehmann MH, Masanetz S, Kramer S, Erfle V.

J Cell Sci. 2006 Nov 1;119(Pt 21):4520-30. Epub 2006 Oct 17.

21.

Extracellular HIV-1 Nef increases migration of monocytes.

Lehmann MH, Walter S, Ylisastigui L, Striebel F, Ovod V, Geyer M, Gluckman JC, Erfle V.

Exp Cell Res. 2006 Nov 1;312(18):3659-68. Epub 2006 Aug 16.

PMID:
16978607
22.

Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity.

Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, Sutter G.

Virology. 2006 Jul 5;350(2):276-88. Epub 2006 Apr 3.

23.

Prion infection influences murine endogenous retrovirus expression in neuronal cells.

Stengel A, Bach C, Vorberg I, Frank O, Gilch S, Lutzny G, Seifarth W, Erfle V, Maas E, Schätzl H, Leib-Mösch C, Greenwood AD.

Biochem Biophys Res Commun. 2006 May 12;343(3):825-31. Epub 2006 Mar 15.

PMID:
16564028
24.

Analysis of the influence of subcellular localization of the HIV Rev protein on Rev-dependent gene expression by multi-fluorescence live-cell imaging.

Wolff H, Hadian K, Ziegler M, Weierich C, Kramer-Hammerle S, Kleinschmidt A, Erfle V, Brack-Werner R.

Exp Cell Res. 2006 Feb 15;312(4):443-56.

PMID:
16368434
25.

Vaccines based on Nef and on Nef/DeltaV2 Env.

Erfle V, Goebel FD, Guzman CA, Le Grand R.

Microbes Infect. 2005 Nov;7(14):1400-4. Epub 2005 Sep 15.

PMID:
16243564
26.
27.

Cell line dependent RNA expression profiles of prion-infected mouse neuronal cells.

Greenwood AD, Horsch M, Stengel A, Vorberg I, Lutzny G, Maas E, Schädler S, Erfle V, Beckers J, Schätzl H, Leib-Mösch C.

J Mol Biol. 2005 Jun 10;349(3):487-500. Epub 2005 Apr 12.

PMID:
15896347
28.

Identification of a novel Rev-interacting cellular protein.

Kramer-Hämmerle S, Ceccherini-Silberstein F, Bickel C, Wolff H, Vincendeau M, Werner T, Erfle V, Brack-Werner R.

BMC Cell Biol. 2005 Apr 24;6(1):20.

29.

The distribution of pol containing human endogenous retroviruses in non-human primates.

Greenwood AD, Stengel A, Erfle V, Seifarth W, Leib-Mösch C.

Virology. 2005 Apr 10;334(2):203-13.

30.

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

Mäkitalo B, Lundholm P, Hinkula J, Nilsson C, Karlén K, Mörner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R.

J Gen Virol. 2004 Aug;85(Pt 8):2407-19.

PMID:
15269383
31.

Autologous cytotoxicity of natural killer cells derived from HIV-infected patients.

Hultström AL, Bratt G, Cosma A, Erfle V, Wahren B, Carbone E.

Immunol Lett. 2004 Feb 15;91(2-3):155-8.

PMID:
15019284
32.

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Cosma A, Bühler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, Sutter G.

Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10.

33.

Analysis of nuclear targeting activities of transport signals in the human immunodeficiency virus Rev protein.

Demart S, Ceccherini-Silberstein F, Schlicht S, Walcher S, Wolff H, Neumann M, Erfle V, Brack-Werner R.

Exp Cell Res. 2003 Dec 10;291(2):484-501.

PMID:
14644169
34.

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Marthas ML, Erfle V, Wolinsky SM, Wang C, Allison DB, Rud EW, Wilson N, Montefiori D, Altman JD, Watkins DI.

J Virol. 2003 Dec;77(24):13348-60.

35.

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.

Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V.

Vaccine. 2003 Dec 8;22(1):21-9.

PMID:
14604567
36.

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Hornemann S, Harlin O, Staib C, Kisling S, Erfle V, Kaspers B, Häcker G, Sutter G.

J Virol. 2003 Aug;77(15):8394-407.

37.

Improved host range selection for recombinant modified vaccinia virus Ankara.

Staib C, Löwel M, Erfle V, Sutter G.

Biotechniques. 2003 Apr;34(4):694-6, 698, 700. No abstract available.

PMID:
12703290
38.

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22. Epub 2002 Dec 23.

39.

Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.

Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin AM, Sutter G, Erfle V, Girard M.

DNA Cell Biol. 2002 Sep;21(9):653-8.

PMID:
12396607
40.

Differences between T cell epitopes recognized after immunization and after infection.

Vogel TU, Horton H, Fuller DH, Carter DK, Vielhuber K, O'Connor DH, Shipley T, Fuller J, Sutter G, Erfle V, Wilson N, Picker LJ, Watkins DI.

J Immunol. 2002 Oct 15;169(8):4511-21.

41.
42.

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI.

J Virol. 2002 Jul;76(14):7187-202.

43.

Different activities of type I interferons on hepatitis B virus core promoter regulated transcription.

Schulte-Frohlinde E, Seidler B, Burkard I, Freilinger T, Lersch C, Erfle V, Foster GR, Classen M.

Cytokine. 2002 Feb 21;17(4):214-20.

PMID:
11991674
44.

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

Nilsson C, Sutter G, Walther-Jallow L, ten Haaft P, Akerblom L, Heeney J, Erfle V, Böttiger P, Biberfeld G, Thorstensson R.

J Gen Virol. 2002 Apr;83(Pt 4):807-18.

PMID:
11907330
45.

HIV-1 Nef co-localizes with the astrocyte-specific cytoskeleton protein GFAP in persistently nef-expressing human astrocytes.

Kohleisen B, Hutzler P, Shumay E, Ovod V, Erfle V.

J Neurovirol. 2001 Feb;7(1):52-5.

PMID:
11519482
46.
47.

HIV type 1 Nef promotes neoplastic transformation of immortalized neural cells.

Kramer-Hämmerle S, Kohleisen B, Hohenadl C, Shumay E, Becker I, Erfle V, Schmidt J.

AIDS Res Hum Retroviruses. 2001 May 1;17(7):597-602.

PMID:
11375055
48.

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

Nilsson C, Mäkitalo B, Berglund P, Bex F, Liljeström P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R.

Vaccine. 2001 May 14;19(25-26):3526-36.

PMID:
11348720
49.

Nucleocytoplasmic transport in human astrocytes: decreased nuclear uptake of the HIV Rev shuttle protein.

Neumann M, Afonina E, Ceccherini-Silberstein F, Schlicht S, Erfle V, Pavlakis GN, Brack-Werner R.

J Cell Sci. 2001 May;114(Pt 9):1717-29.

50.

Cell type-specific expression and promoter activity of human endogenous retroviral long terminal repeats.

Schön U, Seifarth W, Baust C, Hohenadl C, Erfle V, Leib-Mösch C.

Virology. 2001 Jan 5;279(1):280-91.

Supplemental Content

Support Center